Deafness and Blindness clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
open to eligible people ages 8 years and up
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
San Francisco 5391959, California 5332921 and other locations
Last updated: